Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Adenocarcinoma of Stomach or Esophagogastric Junction”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06118658
What this trial is testing

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Who this might be right for
GastricColorectal Adenocarcinoma
China Medical University, China 30
Testing effectiveness (Phase 2)UnknownNCT05625737
What this trial is testing

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Who this might be right for
Stomach Neoplasms
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 29
Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767
What this trial is testing

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 100
Large-scale testing (Phase 3)Study completedNCT05052801
What this trial is testing

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Amgen 547
Testing effectiveness (Phase 2)Study completedNCT00061932
What this trial is testing

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachIntestinal Adenocarcinoma of the Stomach+5 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07609667
What this trial is testing

SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma

Who this might be right for
Gastroesophageal Junction Adenocarcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 80
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85
Large-scale testing (Phase 3)Looking for participantsNCT06221748
What this trial is testing

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd. 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT06939452
What this trial is testing

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Yongxu Jia 37
Large-scale testing (Phase 3)Not Yet RecruitingNCT07677293
What this trial is testing

Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

Who this might be right for
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Peking University 332
Testing effectiveness (Phase 2)Study completedNCT02096666
What this trial is testing

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Who this might be right for
Stomach Neoplasms
Amgen 11
Large-scale testing (Phase 3)Active Not RecruitingNCT04208347
What this trial is testing

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Who this might be right for
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital 580
Testing effectiveness (Phase 2)Active Not RecruitingNCT06576921
What this trial is testing

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Who this might be right for
Stomach NeoplasmsImmune Checkpoint Inhibitors
Xijing Hospital 116
Testing effectiveness (Phase 2)Study completedNCT01364493
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Peking University 51
Post-approval studies (Phase 4)Not Yet RecruitingNCT07149181
What this trial is testing

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Liaoning Cancer Hospital & Institute 1,000
Early research (Phase 1)Active Not RecruitingNCT04535401
What this trial is testing

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Who this might be right for
Advanced Colorectal CarcinomaAdvanced Digestive System CarcinomaAdvanced Gastric Carcinoma+11 more
National Cancer Institute (NCI) 10
Large-scale testing (Phase 3)Not Yet RecruitingNCT07700979
What this trial is testing

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Akeso 900
Large-scale testing (Phase 3)WithdrawnNCT04859582
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)Looking for participantsNCT06932068
What this trial is testing

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Who this might be right for
HER2 NegativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University 77
Next Page